Form 4: Indaptus Director Ben-Tzvi Boosts Stake with Stock, Options

Indaptus Therapeutics Director Avraham Ben-Tzvi acquired 25,000 shares of restricted common stock and 25,000 stock options as part of compensation.

Summary

• Avraham Ben-Tzvi, a Director of Indaptus Therapeutics, Inc. (INDP), reported changes in his beneficial ownership.
• Acquired 25,000 shares of restricted common stock on January 20, 2026, at a price of $0.00 per share, which vested 100% upon grant pursuant to a consulting agreement.
• Acquired options to purchase 25,000 shares of common stock on December 23, 2025, with an exercise price of $1.95 per share.
• The stock options vest over three years commencing from the date of grant in equal quarterly installments, subject to continued service on the Board through each vesting date.
• Following these transactions, Ben-Tzvi beneficially owns 25,100 shares of common stock, which includes 100 shares held in a Roth IRA, and 25,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director, even as compensation, generally indicates alignment of interests and potential confidence in the company's future, which is a moderately positive signal.

Positives

• A director acquiring additional shares and options, even as compensation, can signal confidence in the company's future prospects and aligns management interests with shareholders.
• The immediate vesting of 25,000 restricted common shares provides direct equity ownership.

Risks

• The value of the acquired common stock and options is subject to market fluctuations of Indaptus Therapeutics' share price.
• The stock options' vesting schedule over three years means the director must continue service to fully realize the benefit, posing a risk of forfeiture if service ceases prematurely.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the stock options, which extends over three years.

Industry Context

In the biotechnology and pharmaceutical sectors, compensation packages for directors and executives frequently include equity components like restricted stock and stock options. This practice is designed to align the interests of leadership with those of shareholders, incentivizing long-term value creation in a capital-intensive and research-driven industry.

Comparison to Industry Standards

• The use of restricted stock and stock options as compensation for non-employee directors is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotech.
• The vesting schedule for options over three years is typical for encouraging long-term commitment and performance, comparable to similar programs at peer companies in the biopharmaceutical space.

Corporate Governance

Related Party Transactions

• The acquisition of 25,000 shares of restricted common stock was pursuant to a consulting agreement dated January 20, 2026, between the reporting person and the Issuer.

Stakeholder Impact

• Shareholders: The director's increased equity stake and long-term option vesting align his financial interests with those of shareholders, potentially fostering greater commitment to long-term value creation.
• Employees: No direct impact mentioned, but a stable and committed board can positively influence overall company direction and employee morale.

Next Steps

• The acquired stock options will vest in equal quarterly installments over three years, subject to Avraham Ben-Tzvi's continued service on the Board.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Form 4, Insider Transaction, Director Compensation, Stock Options, Restricted Stock, Beneficial Ownership